Abstract
BC-2 and BC-4 Mabs labelled with 1-131, were given directly in the tumoral bed. 81 glioblastoma evaluable cases were treated. Adverse effects were very few. The treatment lengthened the patients’ median survival (22 months in total). 11 PR, 1 CR and 24 NED (No Evidence of Disease) were recorded. The response rate was 44.4 %. Then a new isotope, Y-90, has been employed. Following a phase I trial, a phase II study was initiated in 22 cases with malignant glioma (anaplastic astrocytoma n.6 and glioblastoma n.16). In 16evaluable patients (12 glioblastoma and 4 anaplastic astrocytoma) the objective response consisted in 1 PD, 4 SD,7 PR,2 CR and 2 NED.The global response rate (PR+ CR+NED) was 68.75% (66.6% in glioblastoma and 75% in anaplastic astrocytoma group).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Ransonhoff J., Kelly P., Laws E. The role of intracranial surgery for the treatment of malignant gliomas. Semin in Oncology 1986; 13:27–37.
Goldenberg D.M., Griffith G.L. Radioimmunotherapy of cancer: arming the missiles. J.Nucl.Med 1992;33: 1110–12.
Riva P., Arista A., Mariani M., Seccamani E., Sturiale C., Tison V., et al. Radioimmunotherapy of brain glioblastoma by direct intratumor injection of 131I labelled BC-2 monoclonal antibody: Clinical experience in 11 patients. In:R. Hofer, H. Bergmenn, H. Sinzinger (eds.) Radio-active Isotopes in Clinical Medicine and Research, Stuttgart, New York: Scattauer; 1992:40–44.
Riva P., Franceschi G., Arista A., Frattarelli M., Riva N., Cremonini A.M., Giuliani G., Casi M. Local application of radiolabeled mabs for the treatment of high grade malignant gliomas: a six year clinical experience. Cancer suppl., 80, 12, 2733-2742, 1997.
Siri A., Carnemolla B., Saginati M, Leprini A., Casari G., Baralle F. et al. Human Tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies. Nuclear Acids Research. 1991; 19:525–31.
World Health Organization handbook for reporting results of cancer treatments. Offsets Publication n.40, 1979. Geneva, Switzerland: WHO, 1979.
Riva P., Arista A., Tison V., Sturiale C., Franceschi G., Spinelli A. et al. Intralesional Radioimmunotherapy of Malignant Glioma: an effective treatment in recurrent tumors. Cancer suppl. 1994;73:1076–82.
Loevinger, R., Berman, M. A schema for absorbed dose calculation for biologically distributed radionuclides. MIRD pamphlet n.1. New York:J Nucl Med.
Riva P., Arista A., Sturiale C., Tison V., Frattarelli M., Lazzari S. et al. Radioimmunotherapy of CNS malignant gliomas by direct intralesional injection of specific 131I radiolabeled monoclonal antibodies. In: Cancer therapy with radiolabeled antibodies. D. M. Goldenberg (ed.) pp.203–216. Boca Raton, Ann Arbor, London, Tokyo. CRC Press, 1994.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Basel AG
About this paper
Cite this paper
Riva, P. et al. (1999). Radioimmunotherapy of Glioblastoma by Using 1-131 and Y-90 Labeled Antitenascin Monoclonal Antibodies. In: Bergmann, H., Köhn, H., Sinzinger, H. (eds) Radioactive Isotopes in Clinical Medicine and Research XXIII. Advances in Pharmacological Sciences. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8782-3_8
Download citation
DOI: https://doi.org/10.1007/978-3-0348-8782-3_8
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-9772-3
Online ISBN: 978-3-0348-8782-3
eBook Packages: Springer Book Archive